These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34904492)

  • 21. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
    Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemigatinib Is Active in Some
    Cancer Discov; 2020 May; 10(5):639. PubMed ID: 32245820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
    Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 29. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
    Gandhy SU; Casak SJ; Mushti SL; Cheng J; Subramaniam S; Zhao H; Zhao M; Bi Y; Liu G; Fan J; Adeniyi O; Charlab R; Kufrin D; Thompson MD; Jarrell K; Auth D; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Oct; 29(20):4027-4031. PubMed ID: 37289037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 33. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
    Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
    Cancer Res Treat; 2024 Jul; 56(3):847-855. PubMed ID: 38351684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
    Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
    Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
    Neuzillet C
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):773-775. PubMed ID: 34358483
    [No Abstract]   [Full Text] [Related]  

  • 39. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
    Ruff SM; Roychowdhury S; Pawlik TM
    Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.